Logo

Castle Biosciences DecisionDx-CMSeq

May 31, 2018

Castle Biosciences has launched its DecisionDx-CMSeq test, which uses next-generation sequencing to identify somatic mutations in BRAF and NRAS, two genes linked to cutaneous melanoma. The DecisionDx-CMSeq test will provide additional information to compliment the firm's DecisionDx-Melanoma gene expression profile (GEP) test that predicts individual risk of melanoma recurrence in patients. The test can be ordered with the DecisionDx-Melanoma GEP test or as a standalone request. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.